AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Switglim MV 2mg/500mg/0.2mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Akumentis Healthcare Ltd

Salt Composition

Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.2mg)

Overview Switglim MV 2mg/500mg/0.2mg Tablet ER

Diabetic patients' blood sugar management can be aided by the anti-diabetic medication, Glimepiride/Metformin/Pioglitazone Extended Release Tablets (2mg/500mg/0.2mg). This triple-combination drug is indicated for adult type 2 diabetes mellitus. Consistent daily use, always at the same time and with food, maximizes its effectiveness. Dosage adjustments are determined by your physician based on your blood sugar readings. Discontinuation requires medical consultation; abrupt cessation can lead to uncontrolled blood sugar, potentially causing kidney damage, vision loss, neuropathy, and limb complications. This medication is part of a comprehensive approach encompassing diet, exercise, and weight management, guided by your physician. Maintaining a healthy lifestyle is crucial. Hypoglycemia (low blood sugar) is the most frequent side effect, characterized by sweating, dizziness, headache, and tremors. Prompt glucose intake (sugary foods or juice) is essential for management. Alcohol should be avoided as it increases hypoglycemia risk. Other possible side effects include altered taste, nausea, diarrhea, abdominal pain, headache, edema, blurred vision, bone fractures, upper respiratory infections, and weight gain. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe liver or kidney disease. Individuals with a history of heart disease should consult their physician before use. Pregnant or lactating women require medical advice prior to use. Regular blood sugar monitoring is necessary, along with potential blood tests to monitor blood cell counts and liver function.

Primary Ingredients of Switglim MV 2mg/500mg/0.2mg Tablet ER

No information provided. Please provide the text you wish me to rephrase.

Uses of Switglim MV 2mg/500mg/0.2mg Tablet ER

Managing type 2 diabetes

Major Benefits of Switglim MV 2mg/500mg/0.2mg Tablet ER:

Follow your physician's instructions precisely regarding dosage and treatment length for this medication. Ingest the Switglim MV 2mg/500mg/0.2mg Extended-Release tablet whole; do not chew, crush, or divide it. Administer on an empty stomach.

Common Side effects of Switglim MV 2mg/500mg/0.2mg Tablet ER:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Hypoglycemia (low blood glucose level)
  • Loss of appetite

How to use Switglim MV 2mg/500mg/0.2mg Tablet ER:

Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment duration. Ingest the entire tablet whole; avoid chewing, crushing, or fracturing it. Consume Switglim MV 2mg/500mg/0.2mg Extended-Release Tablets on an empty stomach.

How Switglim MV 2mg/500mg/0.2mg Tablet ER works:

Extended-release Switglim MV tablets (2mg/500mg/0.2mg) contain a triple-drug formulation for diabetes management.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Switglim MV 2mg/500mg/0.2mg Tablet ER with alcohol is inadvisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Switglim MV tablets (2mg/500mg/0.2mg) might pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The extended-release Switglim MV 2mg/500mg/0.2mg tablet is likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyUNSAFE

Employing Switglim MV 2mg/500mg/0.2mg Extended-Release Tablets in individuals with kidney impairment carries a substantial risk and is best avoided. Medical advice is essential. Furthermore, this medication is contraindicated for patients exhibiting severe kidney dysfunction.

LiverLiverCAUTION

Patients with liver impairment should use Switglim MV 2mg/500mg/0.2mg Extended-Release tablets cautiously. Dosage modification may be necessary for these patients. Medical advice is recommended. In those with mild to moderate liver disease, initiation should be at a low dose; however, Switglim MV 2mg/500mg/0.2mg ER tablets are contraindicated in patients with severe hepatic dysfunction.

What if you forget to take Switglim MV 2mg/500mg/0.2mg Tablet ER :

Should you forget a dose of Switglim MV 2mg/500mg/0.2mg Extended-Release Tablet, ingest it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Switglim MV 2mg/500mg/0.2mg Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Switglim MV 2mg/500mg/0.2mg Tablet ER

Switglim MV 2mg/500mg/0.2mg Extended-Release tablets combine glimepiride, metformin, and voglibose to manage type 2 diabetes mellitus in adults. This combination improves blood glucose control when used with diet and exercise. Glimepiride stimulates insulin release; metformin reduces liver glucose production and enhances insulin sensitivity; and voglibose, an alpha-glucosidase inhibitor, lowers postprandial glucose. This medication is not suitable for type 1 diabetes.
Switglim MV 2mg/500mg/0.2mg ER tablets may cause common side effects including hypoglycemia, nausea, diarrhea, altered taste perception, flatulence, stomach pain, headache, rash, and respiratory infections.
Switglim MV 2mg/500mg/0.2mg Tablet ER is contraindicated in patients allergic to its components or excipients, those with moderate to severe kidney disease, and those with inflammatory bowel disease, colonic ulcers, or underlying metabolic acidosis (including diabetic ketoacidosis).
Combining Switglim MV 2mg/500mg/0.2mg ER tablets with alcohol is unsafe. This combination can worsen low blood sugar (hypoglycemia) and raise the risk of lactic acidosis.
Switglim MV 2mg/500mg/0.2mg ER Tablets can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with skipped meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Regular blood sugar monitoring is crucial. Carry glucose tablets, honey, or fruit juice to treat low blood sugar.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Switglim MV 2mg/500mg/0.2...
118
MRP 137
13% off